Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen VP, Finance & CAO Matthew C. Busch reported a small tax-related share disposition. On the transaction date, 41 shares of Amgen common stock were withheld at $331.11 per share to cover tax obligations related to equity compensation. After this non-market tax-withholding event, Busch directly held 4,344 Amgen shares, which include 39 Dividend Equivalents tied to unvested Restricted Stock Units under the company’s equity incentive plan.
Amgen Inc. executive Esteban Santos reported routine share updates related to compensation and plan holdings. On May 7, 2026, 522 shares of Amgen common stock were disposed of in a tax-withholding transaction at $331.11 per share to satisfy exercise price or tax liabilities. After this, he directly owned 82,847 common shares. He also reported 909.9906 shares held indirectly through a 401K Plan. The reported holdings include 327 Dividend Equivalents credited to unvested Restricted Stock Units, which will be paid in common shares on a one-to-one basis according to their vesting schedule.
Amgen Inc. executive David M. Reese reported a routine tax-related share disposition. On 2026-05-07, 556 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations associated with equity compensation. After this withholding, he directly holds 42,256 shares of Amgen common stock. A footnote also notes 350 Dividend Equivalents tied to unvested Restricted Stock Units that will pay out in shares as they vest.
Amgen Inc. senior vice president of human resources Derek Miller reported a small tax-related share disposition. On May 7, 2026, 151 shares of Amgen common stock were withheld at $331.11 per share to cover tax obligations, a non-market transaction. After this event, Miller directly holds 12,444 shares, which include 99 dividend equivalents tied to unvested restricted stock units that will settle in shares as they vest.
Amgen Inc. senior vice president Rachna Khosla had 93 shares of common stock withheld on May 7, 2026 to cover tax obligations. The shares were valued at $331.11 each. After this tax-withholding disposition, she directly holds 8,394 shares of Amgen common stock.
Amgen Inc. senior vice president and chief compliance officer Nancy A. Grygiel reported routine share activity involving Amgen common stock. The filing shows a tax-withholding disposition of 88 shares of common stock at $331.11 per share, used to cover tax obligations rather than representing an open-market sale. After this transaction, she holds 7,330 Amgen shares directly. The filing also notes an indirect holding of 106.1864 shares in a 401(k) plan, which includes 58 Dividend Equivalents tied to unvested Restricted Stock Units that will be paid out in shares as they vest.
Amgen Inc. executive Peter H. Griffith, EVP & CFO, reported a routine tax-related share disposition. On the reported date, 556 shares of Amgen common stock were surrendered at $331.11 per share to cover tax obligations, a non-market "tax-withholding disposition" rather than an open-market sale.
Following this transaction, Griffith directly held 50,150 shares of Amgen common stock. A footnote explains that his holdings include Dividend Equivalents credited to unvested Restricted Stock Units under Amgen’s equity incentive plan, which are paid in shares as those awards vest.
Amgen Inc. executive Jonathan P. Graham reported a small tax-related share disposition. On the transaction date, 499 shares of Amgen common stock were withheld at $331.11 per share to cover exercise price or tax liability, a routine administrative event rather than an open-market sale.
After this tax-withholding disposition, Graham directly held 39,712 Amgen shares. His holdings include 311 Dividend Equivalents granted under Amgen’s equity incentive plan, which are tied to unvested Restricted Stock Units and pay out in shares on a one-to-one basis as those awards vest.
Amgen Inc. executive vice president of Global Commercial Operations Murdo Gordon reported a small stock transaction related to taxes. On a Form 4, he showed a tax-withholding disposition of 615 shares of Amgen common stock at $331.11 per share, a mechanistic step to cover obligations associated with equity compensation rather than an open-market sale. After this transaction, he directly holds 51,222 shares of Amgen common stock. The reported holdings include 386 Dividend Equivalents tied to unvested restricted stock units under Amgen’s equity incentive plan, which will be paid out in shares as those units vest.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported a routine tax-withholding transaction in company stock. On 2026-05-07, 2,079 shares of Amgen common stock were withheld at $331.11 per share to satisfy tax obligations, not as an open-market sale.
Following this withholding, Bradway directly owns 505,160 shares of Amgen common stock. He also reports indirect holdings through related parties, including shares held by his spouse and in spousal GRAT and GRAT vehicles, reflecting additional indirect economic exposure to Amgen stock.